FDA Evaluating Link Between Byetta and Pancreatic Cancer

In March of this year, the Food and Drug Administration released the following safety alert: “Incretin Mimetic Drugs for Type 2 Diabetes: Early Communication – Reports of Possible Increased Risk of Pancreatitis and Pre-cancerous Findings of the Pancreas.”

The FDA reports that it is evaluating academic research that links these drugs with the elevated risk in patients of developing pancreatitis (acute inflammation of the pancreas) and pancreatic ductal metaplasia (the transformation of cells of the pancreas from a normal state into a pre-cancerous one).

The FDA alert refers to the drugs which mimic incretin hormones produced by the body to stimulate insulin after ingesting food. These drugs include:

– Exenatide (packaged under the product names Byetta and Bydureon),
– Liraglutide (Victoza),
– Sitagliptin (Januvia, Janumet, Janumet XR, Juvisync),
– Saxagliptin (Onglyza, Kombiglyze XR),
– Alogliptin (Nesina, Kazano, Oseni), and
– Linagliptin (Tradjenta, Jentadueto).

Byetta is already known to cause serious side effects. These can include:

– Allergic reactions: hives, swelling of the throat, lips or face
– Bodily swelling or sudden weight gain
– Shortness of breath
– Cessation of urination or diarrhea
– Drowsiness or confusion
– Pain in lower or middle back
– Severe stomach pain and vomiting
– Nausea
– Dizziness, headaches or jitters

If you are taking Byetta and experience any of the above, call your doctor at once. The FDA also requests that these symptoms be reported so that the data may be included in further studies of this product. And if you are taking Byetta and have been diagnosed with pancreatic cancer, you may be facing enormous medical expenses that insurance will not cover.

If that is the case, the attorneys of The Levensten Law Firm urge you to call us to learn how to protect your rights to compensation.